Results 311 to 320 of about 85,787 (336)

A randomized phase II study of cabiralizumab (cabira) + nivolumab (nivo) ± chemotherapy (chemo) in advanced pancreatic ductal adenocarcinoma (PDAC).

Journal of Clinical Oncology, 2019
TPS465 Background: Treatment options for PDAC are limited; thus, new therapies that can improve outcomes and extend survival are needed. PDAC is associated with high infiltration by tumor-associated macrophages (TAMs) that inhibit antitumor T-cell ...
A. Wang-Gillam, E. O’Reilly, J. Bendell, Z. Wainberg, E. Borazanci, N. Bahary, M. O'Hara, G. Beatty, S. Pant, D. Cohen, S. Leong, M. Beg, Kenneth H. Yu, T. Evans, T. Seufferlein, T. Okusaka, P. Phillips, Xuan Liu, S. Perna, D. Le   +19 more
semanticscholar   +1 more source

Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC)

Expert Opinion on Investigational Drugs, 2018
Introduction: Prognosis remains dismal for pancreatic ductal adenocarcinoma (PDAC). Genomics and proteomics have depicted heterogeneity in PDAC. Collectively, this information could be useful in improving diagnosis, prognosis, modalities of therapy ...
S. Chandana, H. Babiker, D. Mahadevan
semanticscholar   +1 more source

Personalized Models of Human PDAC

2020
Pancreatic cancer is one of the most aggressive malignancies with large inter- and intratumoural heterogeneity and an extremely poor prognosis. Uniform treatments adapted to disease states, but ignoring the individual cancer biology, are still the standard of care. Yet, response to therapy varies substantially among pancreatic cancer patients, and most
Hanna Heikenwälder, Susanne Roth
openaire   +1 more source

NUFIP1+ stroma keeps PDAC fed

Nature Cancer, 2022
Holly Sandborg, Mara H. Sherman
openaire   +2 more sources

Gasdermin E shields PDAC

Nature Reviews Cancer, 2022
openaire   +2 more sources

EZH2i unlocks PDAC immune surveillance

Nature Cancer, 2023
Helene Damhofer, Kristian Helin
openaire   +2 more sources

Epigenetic plasticity in PDAC

Nature Cancer, 2023
openaire   +2 more sources

Vps34 role in PDAC carcinogenesis

2022
Introduction Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with poor prognosis. Although the importance of the activating mutation of KRAS, observed in 95% of these cancers, in initiation is recognized, most of the cellular and molecular mechanisms downstream of KRAS controlling the aggressiveness and heterogeneity of this cancer remain ...
Guyon, Camille, Ramos-Delgado, Fernanda, Thibault, Benoît, Therville, Nicole   +3 more
openaire   +1 more source

PDAC POSTER

2020
Senol, Naci Sertug, Gregory, Daniel D.
openaire   +1 more source

Nociceptor neurons promote PDAC progression and cancer pain by interaction with cancer-associated fibroblasts and suppression of natural killer cells

Cell Research
Kaiyuan Wang, Bo Ni, Yongjie Xie, Zekun Li, Limei Yuan, Chenyang Meng, Tiansuo Zhao, Song Gao, Chongbiao Huang, Hongwei Wang, Ying Ma, Tianxing Zhou, Yukuan Feng, Antao Chang, Chao Yang, Jun Yu, Wenwen Yu, Fenglin Zang, Yanhui Zhang, Ru-Rong Ji, Xiuchao Wang, Jihui Hao   +21 more
semanticscholar   +1 more source